title: Salmonella expressing detoxified lipopolysaccharide is immunogenic and protective both as an attenuated vaccine and for delivery of foreign antigens.
abstract: The construction of safe and protective vaccines, derived from human pathogens that have been genetically modified to remove pathogenicity, is often easier to accomplish on paper than it is in the laboratory. Kong and colleagues have pursued a clever strategy to reduce the reactogenicity of attenuated Salmonella oral vaccines by genetically modifying the surface lipopolysaccharide to lower endotoxic activity. The resulting candidate vaccine strains were highly reduced in virulence yet were able to confer protection in a mouse model against challenge with virulent Salmonella. Remarkably, these strains could also be further modified to present foreign antigens from unrelated human pathogens and again confer protection against heterologous challenge. This work brings important new tools to bear on solving the problem of creating efficacious attenuated bacterial vaccines that maximize both safety and immunogenicity in clinical trials.
authors.affiliation: Center for Vaccine Development, University of Maryland, Baltimore, MD 21201, USA. jgalen@medicine.umaryland.edu
authors.forename: James E
authors.initials: JE
authors.lastname: Galen
authors.forename: Raphael
authors.initials: R
authors.lastname: Simon
authors.forename: Robert K
authors.initials: RK
authors.lastname: Ernst
references.citation: J Clin Invest. 1987 Mar;79(3):888-902
references.pmid: 3818953
references.citation: Infect Immun. 2010 Sep;78(9):3969-80
references.pmid: 20605977
references.citation: Vaccine. 2007 May 22;25(21):4175-82
references.pmid: 17412462
references.citation: Vaccine. 1996 Jan;14(1):19-24
references.pmid: 8821644
references.citation: J Infect Dis. 1996 Jun;173(6):1408-14
references.pmid: 8648213
references.citation: J Immunol. 2009 Nov 15;183(10):6186-97
references.pmid: 19864596
references.citation: Genes Immun. 2006 Jul;7(5):372-83
references.pmid: 16738669
references.citation: Nat Immunol. 2002 Jul;3(7):667-72
references.pmid: 12055629
references.citation: Cell Mol Life Sci. 2008 Oct;65(20):3231-40
references.pmid: 18668203
references.citation: Clin Immunol. 2000 Nov;97(2):146-53
references.pmid: 11027455
references.citation: Vaccine. 2011 Jun 15;29(27):4453-9
references.pmid: 21527299
references.citation: Crit Rev Immunol. 2010;30(3):255-70
references.pmid: 20370633
references.citation: J Immunol. 2011 Jul 1;187(1):412-23
references.pmid: 21632711
references.citation: Vaccine. 2000 Feb 14;18(15):1473-84
references.pmid: 10618545
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):593-8
references.pmid: 19114649